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INTRODUCTION
Correct use of inhaler devices is fundamental to effective asth-
ma management but represents an important challenge for pa-
tients. Both bronchodilator reliever therapy (short-acting β2-
agonist [SABA]) and most asthma controller (preventer) thera-
pies, including inhaled corticosteroids (ICS) and long-acting 
β2-agonist (LABA), are delivered by inhalation. Numerous clin-
ical investigations report errors in inhaler device handling by 
patients, even by those classified as experienced in using their 
asthma inhalers.
1-4 Inhaler mishandling, in turn, has been linked 
to reduced asthma control, with increased risk of exacerbations 
and unscheduled care for asthma.
1,5
The correct inhalation manoeuvre differs for different inhaler 
types.
6-9 Pressurised metered-dose inhalers (pMDIs) are actuat-
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ed by pressing down on the canister to release a dose in coordi-
nation with the start of inhalation. Breath-actuated metered-dose 
inhalers (BAIs) and dry powder inhalers (DPIs) are actuated by 
the patient’s inhalation but vary in requirements for inhalation 
speed and character, which should be slow and deep with a BAI 
but sharp and rapid with a DPI.
Because of these differences, several authors have recommend-
ed that patients should always be prescribed the same device 
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Purpose:  Correct use of inhaler devices is fundamental to effective asthma management but represents an important challenge for patients. The 
correct inhalation manoeuvre differs markedly for different inhaler types. The objective of this study was to compare outcomes for patients prescribed 
the same inhaler device versus mixed device types for asthma controller and reliever therapy.  Methods:  This retrospective observational study 
identified patients with asthma (ages 4-80 years) in a large primary care database who were prescribed an inhaled corticosteroid (ICS) for the first 
time. We compared outcomes for patients prescribed the same breath-actuated inhaler (BAI) for ICS controller and salbutamol reliever versus mixed 
devices (BAI for controller and pressurised metered-dose inhaler [pMDI] for reliever). The 2-year study included 1 baseline year before the ICS prescrip-
tion (to identify and correct for confounding factors) and 1 outcome year. Endpoints were asthma control (defined as no hospital attendance for asth-
ma, oral corticosteroids, or antibiotics for lower respiratory tract infection) and severe exacerbations (hospitalisation or oral corticosteroids for asth-
ma).  Results:  Patients prescribed the same device (n=3,428) were significantly more likely to achieve asthma control (adjusted odds ratio, 1.15; 
95% confidence interval [CI], 1.02-1.28) and recorded significantly lower severe exacerbation rates (adjusted rate ratio, 0.79; 95% CI, 0.68-0.93) than 
those prescribed mixed devices (n=5,452).  Conclusions:  These findings suggest that, when possible, the same device should be prescribed for 
both ICS and reliever therapy when patients are initiating ICS.
Key Words:  Asthma; breath-actuated inhaler; inhaled corticosteroids; inhaler device; pressurised metered-dose inhaler; short-acting β2-agonist
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type for each asthma medication.
7-11 It would seem logical that 
confusion could result from using different inhaler device types 
for asthma controller and reliever therapy, especially for patients 
just beginning inhaler therapy who lack long-term training and 
practice with different devices. However, there is actually little 
definitive research into this topic. In their observational study 
of 321 adult outpatients with asthma, van der Palen and coau-
thors
12 used a check-list to assess inhaler technique and found 
no errors among 71% of patients using only one inhaler as com-
pared with 61% of patients using two or more different inhalers. 
They concluded that the same type of inhaler should be pre-
scribed and that if this is not possible then a combination of two 
different DPIs is preferable to a DPI-pMDI combination. They 
did not examine asthma control in relation to inhaler technique, 
nor, to our knowledge, have other studies investigated this.
Retrospective database studies can be used to examine the 
comparative effectiveness of interventions for real-world pa-
tients under real-world conditions of clinical care. Our objec-
tive in this study was to determine whether outcomes differed 
for primary care patients in the UK who were prescribed the 
same BAI device for asthma controller and reliever therapy as 
compared with mixed devices (BAI plus pMDI). We focused on 
BAIs, as these are often used for controller therapy but not always 
in conjunction with a breath-actuated reliever because the lat-
ter is more expensive than a SABA pMDI.
MATERIALS AND METHODS
Data source and patients
This retrospective observational study drew on anonymised 
patient data contained in the General Practice Research Data-
base (GPRD), a large primary care database containing pre-
scription and other medical record information for patients at 
over 500 participating clinical practices throughout the UK.
13 
The GPRD is a well-regarded and validated data source for 
pharmacoepidemiologic research, including respiratory and 
prescribing research.
14-18
This study analysed data for patients with asthma aged 4-80 
years who received beclometasone dipropionate by Easi-Breathe 
BAI as their first ICS prescription, together with a prescription 
for reliever therapy (salbutamol) by either Easi-Breathe BAI or 
pMDI. These particular combinations allowed for comparabili-
ty of formulation and drug, as salbutamol pMDI and BAI con-
tain a pressurised aerosol with similar characteristics and the 
only difference being between the breath actuation amend-
ments. Evidence of asthma in the database was defined as a 
coded diagnosis of asthma, two or more prescriptions for asth-
ma at different timepoints during the baseline year, or two or 
more prescriptions for asthma during the outcome year that in-
cluded at least one ICS prescription. Patients over 60 years old 
who smoked were excluded from the study to minimise inclu-
sion of patients with concomitant chronic obstructive pulmo-
nary disease (COPD). In addition to COPD, other exclusion cri-
teria were any other chronic respiratory disease, a prescription 
for asthma controller therapy (ICS or LABA) during the baseline 
year, or a LABA prescription at the index date.
The study period spanned 16 and a half years from January 
1991 through June 2007, a period when all devices of interest 
were available. As SABA is not always prescribed on the same 
day as ICS, we prioritised as follows to identify each patient’s 
salbutamol device for the study: (1) the salbutamol prescribed 
at the index date; (2) the salbutamol prescribed at the closest 
date before the index date; or (3) the first salbutamol prescribed 
after the index date if there were no recorded prescriptions be-
fore the index date. Eligible patients were required to have 2 
continuous years of data in the GPRD, including a baseline year 
for confounder definition and an outcome year, and to be en-
rolled at practices with data assessed as up-to-standard by the 
GPRD during the years in question.
Effectiveness endpoints
The co-primary endpoints, defined in Table 1, were designed 
to capture evidence of asthma control and rate of severe exac-
erbations during the outcome year, in accordance with recom-
mendations of the joint European Respiratory Society/Ameri-
can Thoracic Society Task Force on outcome measures for asth-
ma trials.
19
Secondary endpoints included two composite measures of 
treatment success and the rate of respiratory-related hospitali-
sations (Table 1).
Statistical analyses
Summary statistics were used to assess all baseline and out-
come variables. Continuous variables were compared using the 
t test for normally distributed data and the Mann-Whitney test 
(Wilcoxon rank sum test) for skewed data; categorical variables 
were compared using the χ2 test. Differences between treatment 
cohorts with P<0.10 were examined for collinearity as well as 
clinical importance to select those used as potential confound-
ers in the regression modelling of outcomes.
Multivariate analyses were used to identify baseline variables 
predictive (P<0.05) of outcomes; these were considered as po-
tential additional confounders when modelling outcome vari-
ables. Spearman correlation coefficients were calculated be-
tween all potential confounders to determine strengths of linear 
relationships between variables; the correlation coefficients 
were considered, in conjunction with clinical interpretation, to 
identify possible collinearity issues. All outcomes were adjusted 
for appropriate non-collinear baseline confounders.
The adjusted odds of achieving asthma control was compared 
between treatment cohorts using a binary logistic regression 
model. Asthma control status was used as the dependent vari-
able with treatment and potential confounding factors as ex-
planatory variables. The same model was used to assess other Price et al.
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binary outcomes. A Poisson regression model was used to com-
pare the total number of severe exacerbations in the outcome 
period between treatment cohorts and to obtain estimates of 
exacerbation rates. The model was adjusted for over-dispersion 
using robust standard errors, and adjustments were made for 
potential baseline confounders. This model was used also to 
analyse respiratory-related hospitalisation rates.
Study endpoints and the main analyses were established a 
priori according to standard operating procedures of the study 
group.
20 We also performed a post hoc sensitivity analysis to ex-
plore differences in odds of asthma control and severe exacer-
bation rates after excluding children (ages 4-11) as well as pa-
tients receiving the highest doses of ICS at the index date.
Adjusted odds ratios and rate ratios were calculated together 
with 95% confidence intervals. Statistical significance was de-
fined as P<0.05 and trends as 0.05≤P<0.10. All analyses were 
carried out using SPSS/PASW versions 17 and 18 (SPSS Statis-
tics, IBM, Somers, NY, USA), SAS version 9.2 (SAS Institute, 
Marlow, Buckinghamshire, UK), and Excel 2007 (Microsoft, 
Bellevue, WA, USA).
RESULTS
Patients
We identified 8,880 patients who met study selection criteria: 
3,428 in the same device cohort (who received Easi-Breathe in-
halers for both beclometasone and salbutamol) and 5,452 in 
the mixed devices cohort (who received beclometasone by Ea-
si-Breathe and salbutamol by pMDI). Fig. 1 depicts the patient 
selection process, and Table 2 summarises patient characteris-
tics at the index date. Approximately one quarter (2,107 or 23.7%) 
of patients were children aged 4-11 years. Of these, 45% were 
girls, whereas in the full cohort, 59% were female. The mean year 
of the index date was 1999 in both cohorts.
There were several statistically significant differences in de-
mographic characteristics between the cohorts at baseline (Ta-
ble 2), with proportionately more female patients and more 
Table 1.  Study endpoint definitions
Asthma control,* includes all of the following:
1.   no recorded hospital attendance for asthma, including admission, A&E at-
tendance, out-of-hours attendance, or OPD attendance;
2.   no prescription for oral corticosteroids; and
3.   no general practice consultation, hospital admission, or A&E attendance 
for LRTI requiring antibiotics
Severe exacerbation,* defined as any of the following:
1.   unscheduled hospital admission or A&E attendance for asthma, or
2.   a prescription for oral corticosteroids
Treatment success-1, includes all of the following:
1.   no severe exacerbations;
2.   no consultations, hospital admissions, or A&E attendance for LRTI requir-
ing antibiotics; and
3.   no change in therapeutic regimen, where a change could be any of the 
following:
a. ≥50% increase in ICS dose,
b. change in ICS,
c. change in ICS inhaler device, or
d. use of additional therapy for asthma, including theophylline or LTRA
Treatment success-2,
† includes all of the following:
1.   no severe exacerbations;
2.   no consultations, hospital admissions, or A&E attendance for LRTI requir-
ing antibiotics; and
3.   no change in therapeutic regimen, where a change could be any of the 
following:
a. ≥50% increase in ICS dose, or
b. use of additional therapy for asthma, including theophylline or LTRA
Respiratory-related hospitalisations, including respiratory-related referrals
*Co-primary endpoints; 
†Treatment success-2 differs from treatment success-1 
in excluding the changes in therapeutic regimen that could be attributed to cost-
saving measures.
A&E, Accident & Emergency; ICS, inhaled corticosteroid; LRTI, lower respirato-
ry tract infection; LTRA, leukotriene receptor antagonist; OPD, Outpatient De-
partment.
Fig. 1.  Flow diagram for selection of patient data in the General Practice Re-
search Database
Assessed for eligibility: Patients in the GPRD with 
respiratory disease or rhinitis and 2 or more 
prescriptions (n=815,377)
Patients in the GPRD initiating ICS as beclometasone 
via Easi-Breathe inhaler 1991-2007 
and salbutamol by Easi-Breathe or pMDI
(n=21,495)
Patients prescribed ICS Easi-Breathe 
& fulfilling inclusion criteria (n=13,747)
Patients prescribed ICS Easi-Breathe and 
salbutamol Easi-Breathe or pMDI
(n=8,880)
Same device cohort (n=3,428)
Treatment cohort
Identification 
of patients in 
the GPRD
Mixed device cohort (n=5,452)
Excluded (n=793,882)
¨  Not receiving ICS (n=561,212)
¨  ICS other than beclometasone via Easi-
Breathe (n=226,366)
¨  Prescribed LABA (n=280)
¨  Prescribed no reliever, not salbutamol, 
or >1 reliever (n=6,024)
Excluded (n=7,748)
¨  COPD diagnosis (n=2,407)
¨  Other chronic respiratory disease (n=67)
¨  Age <4 or >80 (n=2,012)
¨  No evidence of asthma (n=2,512)
¨  Maintenance steroids at baseline (n=35)
¨  Age 61-80 and current or former smoker 
(n=715)
Excluded (n=4,867)
¨  Not registered at practice 1yr before 
& 1yr after index date (n=754)
¨  Salbutamol inhaler device not definite 
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Table 2.  Baseline demographic and clinical characteristics of patients with 
asthma receiving their first ICS prescription via BAI together with salbutamol 
via BAI (same device) or with salbutamol via pMDI (mixed devices)
Characteristic
Same device 
(n=3,428)
Mixed devices 
(n=5,452)
P value*
Female sex, n (%) 2,109 (61.5) 3,101 (56.9) <0.001
Age at index date, median 
(IQR)
31 (13-49) 28 (11-45) <0.001
4-11 yr, n (%) 675 (19.7) 1,432 (26.3) -
12-80 yr, n (%) 2,753 (80.3) 4,020 (73.7) -
Weight (kg), mean (SD)
† 69.9 (22.3) 67.6 (24.1) 0.015
Height (m), mean (SD)
† 1.62 (0.15) 1.60 (0.20) 0.315
BMI (kg/m
2), mean (SD)
† 26.0 (6.6) 25.3 (6.6) <0.001
BMI (kg/m
2) >30, n (%)
† 556 (22.4) 763 (19.6) -
Socioeconomic status,  
median (IQR)
‡ 
17.6 (8.1-32.7) 16.4 (8.7-32.7) 0.016
Charlson comorbidity index, 
n (%)
‡ 
0 3,059 (89.2) 4,975 (91.3) 0.002
≥1 369 (10.8) 477 (8.7)
Recorded smoking status,  
n/total n (%)
1,357/3,428 (39.6) 2,091/5,452 (38.4)
Current smokers 604/1,357 (44.5) 883/2,091 (42.2) <0.001
Ex-smokers 261/1,357 (19.2) 546/2,091 (26.1)
Non-smokers 492/1,357 (36.3) 662/2,091 (31.7)
Recorded comorbidity, n (%)
Rhinitis 639 (18.6) 980 (18.0) 0.429
Cardiac disease
§ 556 (16.2) 695 (12.7) <0.001
GERD
§ 445 (13.0) 655 (12.0) 0.178
1+ prescription in 12 mo,  
n (%)
NSAID 623 (18.2) 888 (16.3) 0.021
Beta blocker 172 (5.0) 212 (3.9) 0.011
Paracetamol 644 (18.8) 1,142 (20.9) 0.013
*Categorical values were compared with the χ2 test and continuous variables 
with the Mann-Whitney test; 
†Weight and height were recorded closest to the 
index date; for children <12, weight and height were included only if within 2 
years of index date. Not all patients had recorded weight and height data. For 
weight, n=2,564 (74.8%) and 3,984 (73.1%); height n=2,696 (78.6%) and 4,225 
(77.5%); BMI n=2,483 (72.4%) and 3886 (71.3%) for same and mixed devices 
cohort, respectively; 
‡Socioeconomic status was that assigned, in quintiles, by 
the General Practice Research Database to each practice using the Index of 
Multiple Deprivation as a proxy measure. The Charlson comorbidity index is a 
weighted index that accounts for number and severity of comorbidities, each 
assigned a score depending on the associated risk of dying; 
§Patients with car-
diac disease and GERD included those with a recorded diagnosis or recorded 
prescription for same.
BAI, breath-actuated inhaler; BMI, body mass index; GERD, gastro-oesophageal 
reflux disease; ICS, inhaled corticosteroid; IQR, interquartile range; NSAID, non-
steroidal anti-inflammatory drug; pMDI, pressurised metered-dose inhaler; SD, 
standard deviation.
Table 3.  Asthma-related parameters and medical resource use during the 
baseline year before the first ICS prescription for patients prescribed ICS and 
salbutamol via same or mixed inhaler device type
Characteristic Same device 
(n=3,428)
Mixed devices 
(n=5,452)
P value*
Recorded asthma diagnosis, 
n (%)
3,147 (91.8) 5,045 (92.5) 0.209
Prior SABA inhaler device type
†
None 2,237 (65.3) 3,516 (64.5) -
pMDI 270 (7.9) 1,519 (27.9)
BAI 848 (24.7) 351 (6.4)
DPI 71 (2.1) 63 (1.2)
Various (BAI + MDI or DPI 
+ pMDI)
2 (0.0) 3 (0.0)
Mean daily SABA use, no. (%)
‡
none 1,525 (44.5) 2,279 (41.8) <0.001
≤3.5 doses/wk 1,118 (32.6) 1,647 (30.2)
>0.5-1 dose/d 566 (16.5) 962 (17.6)
>1 dose/d 219 (6.4) 564 (10.3)
Oral corticosteroid courses, n (%)
0 2,857 (83.3) 4,549 (83.4) 0.441
1 461 (13.4) 700 (12.8)
2 81 (2.4) 157 (2.9)
≥3 29 (0.8) 46 (0.8)
Total severe exacerbations, n (%)
§
0 2,855 (83.3) 4,534 (83.2) 0.518
1 461 (13.4) 712 (13.1)
2 83 (2.4) 160 (2.9)
≥3 29 (0.8) 46 (0.8)
ICS dose prescribed at index date, n (%)
1-200 μg/d 815 (23.8) 1507 (27.6) <0.001
201-400 μg/d 1,985 (57.9) 3,430 (62.9)
401-800 μg/d 250 (7.3) 331 (6.1)
>800 μg/d 378 (11.0) 184 (3.4)
Asthma consultations, n (%)
0  1,457 (42.5) 2,399 (44.0) <0.001
1 1,352 (39.4) 2,054 (37.7)
2 464 (13.5) 651 (11.9)
≥3 155 (4.5) 348 (6.4)
Total consultations, n (%)
0-2 822 (24.0) 1221 (22.4) 0.065
3-4 794 (23.2) 1193 (21.9)
5-6 620 (18.1) 997 (18.3)
7-9 581 (16.9) 944 (17.3)
≥10 611 (17.8) 1,097 (20.1)
Asthma prescriptions, n (%)
1 981 (28.6) 1,458 (26.7) <0.001
2 1,063 (31.0) 1,549 (28.4)
3-4 882 (25.7) 1,463 (26.8)
≥5 502 (14.6) 982 (18.0)
(Continued to the next page)Price et al.
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current smokers in the same device cohort. The median age 
was higher in the same device cohort, and patients were heavi-
er with somewhat higher BMI.
During the baseline year, the proportions of patients in each 
cohort who met study criteria for the asthma control measure 
were similar, as were those who had experienced a severe exac-
erbation (Table 3). Patients in the mixed devices cohort were 
more likely to have received paracetamol, a higher SABA dose, 
and more asthma prescriptions than those in the same device 
cohort during the baseline year (Tables 2 and 3).
At the index date, the median (IQR) prescribed ICS doses were 
400 (400-400) µg and 400 (200-400) µg in the same device and 
mixed devices cohorts, respectively (P<0.001). There were more 
patients in the same device cohort who received a high ICS dose 
(>800 μg/day; Table 3). Of the patients with known height and 
weight who were prescribed doses >800 μg/day, the proportions 
who were obese (body mass index ≥30 kg/m
2) were similar in 
the two cohorts, namely 82/327 (25.1%) and 37/153 (24.2%).
Outcomes
There were several statistically significant differences between 
cohorts in the unadjusted outcomes, summarised in Table 4. 
More patients in the same device cohort consumed a mean 
daily ICS dose of >400 µg/day, and fewer used no SABA, dur-
ing the outcome year, as compared with patients in the mixed 
devices cohort. (The daily ICS and salbutamol doses consumed 
Table 4.  Outcomes over 1 year after the first ICS prescription for patients pre-
scribed ICS and salbutamol via same or mixed inhaler device type
Outcome Same device 
(n=3,428)
Mixed 
devices 
(n=5,452)
P value*
Asthma control,
† n (%) 2,767 (80.7) 4,300 (78.9) -
Treatment success-1, n (%) 2,168 (63.2) 3,338 (61.2) -
Treatment success-2, n (%) 2,388 (69.7) 3,762 (69.0) -
Severe exacerbations, n (%)
0 3,070 (89.6) 4,804 (88.1) 0.176
1 257 (7.5) 450 (8.3)
2 63 (1.8) 123 (2.3)
≥3 38 (1.1) 75 (1.4)
Mean daily salbutamol dose
‡, n (%)
none 281 (8.2) 612 (11.2) <0.001
≤3.5 doses/wk 851 (24.8) 1309 (24.0)
>0.5-1 dose/d 1,159 (33.8) 1,720 (31.5)
>1-2 doses/d 780 (22.8) 1,238 (22.7)
>2 doses/d 357 (10.4) 573 (10.5)
Mean daily ICS dose
‡, n (%)
1-100 µg/d 842 (24.6) 1,696 (31.1) <0.001
101-200 µg/d 1,033 (30.1) 1,709 (31.3)
201-400 µg/d 887 (25.9) 1,297 (23.8)
>400 µg/d 666 (19.4) 750 (13.8)
Disaggregated outcomes of the composite endpoints:
≥1 hospital admission, n (%) 20 (0.6) 32 (0.6) 0.983
≥1 oral corticosteroid course, n (%) 356 (10.4) 643 (11.8) 0.148
≥1 course of antibiotics for LRTI, 
n (%)
384 (11.2) 646 (11.8) 0.618
Change in therapy, n (%) 863 (25.2) 1,449 (26.6) 0.143
≥50% increase in ICS dose, n (%) 445 (13.0) 729 (13.4) 0.597
Change in ICS drug 0 0 -
Change in inhaler device 299 (8.7) 585 (10.7) 0.002
Additional therapy 119 (3.5) 135 (2.5) 0.006
*Categorical values were compared with the χ2 test and continuous variables 
with the Mann-Whitney test; 
†See Table 1 for definitions of study endpoints; 
‡The standard dose of salbutamol in the UK is 200 μg. Thus, patients who used 
≤3.5 doses/wk averaged 1-100 µg/d; those who used >0.5-1 dose/d, 101-200 
µg/d; those who used >1-2 doses/d, 201-400 µg/d; and those who used >2 
doses/d, >400 µg/d. The daily salbutamol and ICS doses consumed during the 
outcome year were calculated as the dispensed amount divided by 365.
ICS, inhaled corticosteroid; LRTI, lower respiratory tract infection.
Table 3.  (Continued from the previous page)  Asthma-related parameters and 
medical resource use during the baseline year before the first ICS prescription for 
patients prescribed ICS and salbutamol via same or mixed inhaler device type
Characteristic Same device 
(n=3,428)
Mixed devices 
(n=5,452)
P value*
Courses of antibiotics for LRTI, n (%)
0 2,744 (80.0) 4,312 (79.1) 0.528
1 497 (14.5) 836 (15.3)
≥2 187 (5.5) 304 (5.6)
Asthma control status,  
n (%)
II
2,345 (68.4) 3,689 (67.7) 0.465
*Categorical values were compared with the χ2 test and continuous variables 
with the Mann-Whitney test; 
†The prior SABA device type was included only 
for the baseline year; thus, because some patients had a pre-baseline SABA 
prescription, ~55% of patients used SABA during the baseline year but only 
~35% of patients had a SABA prescription in the baseline period; 
‡The SABA 
dose is the salbutamol dose equivalent (standard dose in UK is 200 μg).Thus, 
patients who used ≤3.5 doses/wk averaged salbutamol 1-100 µg/d; those who 
used >0.5-1 dose/d, 101-200 µg/d; and those who used >1 dose/d, >200 µg/
d; 
§A severe exacerbation was defined as an occurrence of unscheduled hospi-
tal admission or emergency room attendance for asthma or prescription for oral 
corticosteroids; exacerbations on the index date were included in the baseline 
data; 
IIAsthma control was defined as no hospital attendance for asthma, oral 
corticosteroid course, or antibiotics for LRTI during the baseline year.
BAI, breath-actuated inhaler; DPI, dry powder inhaler; ICS, inhaled corticoste-
roid; LRTI, lower respiratory tract infection; pMDI, pressurised metered-dose in-
haler; SABA, short-acting β2-agonist.
during the outcome year were calculated as the dispensed 
amount divided by 365.) The median (interquartile range [IQR]) 
dose of ICS consumed during the outcome year was 164 µg/day 
(110-329) for patients using the same device versus 137 µg/day 
(55-274) for patients using mixed devices (P<0.001). The medi-
an (IQR) salbutamol doses were the same in both cohorts, name-
ly, 110 µg/day (55-219; P=0.638). Additional therapy was more 
likely to have been prescribed in the same device cohort, while 
a change in ICS device was more likely in the mixed devices co-Asthma Control With Same vs. Mixed Inhaler Devices
Allergy Asthma Immunol Res. 2012 July;4(4):184-191.  http://dx.doi.org/10.4168/aair.2012.4.4.184
AAIR 
189 http://e-aair.org
hort (Table 4).
Patients in the same device cohort were significantly more 
likely to achieve asthma control during the outcome year, and 
they experienced a significantly lower rate of severe exacerba-
tions, than those in the mixed devices cohort (Fig. 2). Moreover, 
treatment success-1 was significantly more likely for patients in 
the same device cohort. There were no differences between co-
horts in the adjusted odds for treatment success-2 or in the ad-
justed rate of respiratory-related hospitalisations (Fig. 2).
Because of recorded differences between cohorts in both pre-
scribed ICS dose at the index date and ICS dose consumed over 
the outcome year, we examined the percentage of patients who 
achieved asthma control according to index date ICS dose. The 
differences between cohorts in asthma control were evident at 
the lower ICS doses, whilst at the higher ICS doses the percent-
ages of patients achieving control in each cohort were similar 
(Table 5).
In a post hoc sensitivity analysis of the asthma control and se-
vere exacerbation endpoints, we excluded 1) patients prescribed 
>800 µg/d at the index date (patients prescribed a high ICS dose 
were more numerous in the same device cohort) as well as 2) 
children younger than 12 years (there were fewer patients under 
the age of 12 in the same device cohort). With these exclusions, 
differences in asthma control and severe exacerbation rates were 
no longer significant but showed a strong signal supporting the 
main analyses, with higher odds of asthma control in the same 
device cohort than in the mixed devices cohort (Fig. 2).
DISCUSSION
The results of this retrospective observational study indicate 
that over 1 year after a first ICS prescription, patients prescribed 
the same inhaler device type for both ICS controller and salbu-
tamol reliever therapy were significantly more likely to achieve 
asthma control than those prescribed mixed devices. Moreover, 
patients prescribed the same inhaler device type had a signifi-
cantly lower recorded rate of severe exacerbations requiring a 
hospital visit or oral corticosteroid course, as well as higher odds 
of treatment success after incorporating changes in therapeutic 
regimen. The two treatment cohorts had comparable rates of 
respiratory-related hospitalisations and odds of treatment suc-
cess after excluding changes in therapeutic regimen that could 
be driven by cost savings.
A small proportion of patients in the same device cohort were 
prescribed a higher ICS dose at the index date than those in the 
mixed devices cohort, and the median ICS dose consumed 
during the outcome year was significantly higher in the same 
device cohort. However, we believe it unlikely that ICS dose in-
fluenced outcomes in favour of the same device cohort. Firstly, 
the sensitivity analysis that excluded patients prescribed high 
doses of beclometasone (>800 μg/day) and paediatric patients 
(ages 4-11) supported the main analyses. Secondly, the differ-
ences between treatment cohorts in the proportion of patients 
achieving asthma control were driven by patients receiving the 
Table 5. Percentages of patients who achieved asthma control, according to in-
dex date ICS dose
SAME devices MIXED devices P value*
ICS Dose at index date, n (%)
1-200 µg/d 83% 81% <0.001
201-400 µg/d 82% 79%
401-800 µg/d 73% 74%
≥801 µg/d 75% 75%
*χ2 test
ICS, inhaled corticosteroid.
Fig. 2.  Study endpoint results (adjusted odds ratios and rate ratios) over 1 year 
after the first ICS prescription for patients prescribed ICS and salbutamol via 
same device (n=3,428) as compared with mixed inhaler device types (n=5,452)
Mixed devices: RR/OR=1.0
*Adjusted for age, sex, paracetamol prescriptions, number of GP surgery con-
sultations, number of GP out-of-hours consultations, GERD diagnosis, and time 
between diagnosis and the index date; **Sensitivity analysis excluded patients 
younger than 12 years and those prescribed >800 µg/day on the index date 
(same device cohort n=2,392; mixed devices cohort n=3,841). Adjusted for 
age, sex, number of GP home visits, number of GP out-of-hours consultations, 
and time between diagnosis and the index date; 
†Adjusted for age, asthma pre-
scriptions, NSAID prescriptions, number of planned OPD visits, number of asth-
ma consultations, number of GP out-of-hours consultations, number of tele-
phone consultations, and time between diagnosis and the index date; 
††Sensi-
tivity analysis excluded patients younger than 12 years and those prescribed 
>800 µg/day on the index date. Adjusted for age, acute oral corticosteroids, 
number of primary care consultations, and time between diagnosis and the in-
dex date; 
‡Adjusted for age, SES, asthma prescriptions, NSAID prescriptions, 
CCI score, number of primary care consultations, ICS dose at the index date, 
and time between diagnosis and the index date; 
§Adjusted for age, SES, asth-
ma prescriptions, NSAID prescriptions, number of primary care consultations, 
number of planned OPD appointments, ICS dose at IPD, and time between di-
agnosis and the index date; 
IIAdjusted for age, baseline number of asthma-re-
lated hospitalisations, number of planned OPD visits, and number of GP out-of-
hours consultations.
CCI, Charlson comorbidity index; GP, general practice; GERD, gastro-oesopha-
geal reflux disease; ICS, inhaled corticosteroid; IPD, index prescription date; 
NSAID, nonsteroidal anti-inflammatory drug; OPD, Outpatient Department; OR, 
odds ratio; RR, rate ratio; SES, socioeconomic status.
  0.3  0.5  0.8  1  1.5  2  2.5
Adjusted odds or rate Ratio (95% CI)
Asthma control, adjusted OR*
1.15 (1.02-1.28)
Asthma control, sensitivity analysis**
1.12 (0.98-1.28)
Severe exacerbations, adjusted RR
†
0.79 (0.68-0.93)
Severe exacerbations, sensitivity analysis
††
0.83 (0.68-1.00)
Treatment success-1, adjusted OR
‡
1.11 (1.01-1.22)
Treatment success-2, adjusted OR
§
1.02 (0.93-1.14)
Respiratory-related hospitalisations, adjusted RR
II
1.30 (0.71-2.38)Price et al.
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lower ICS doses (similar proportions of patients achieved asth-
ma control in the higher ICS dose categories).
The problem and prevalence of incorrect inhaler use have been 
the subject of several reviews over the last decade.
7-9,21 Proposed 
solutions to this problem include educating health-care provid-
ers about different inhaler device characteristics; individualis-
ing inhaler selection; accommodating patient preferences with 
regard to their inhaler device; reinforcing inhaler technique at 
each visit; using tools for training and checking technique; and 
avoiding a switch in ICS device without an accompanying con-
sultation.
9,22,23 The results of this study suggest an additional so-
lution, namely, that, when possible, patients_especially those 
initiating ICS therapy_should be prescribed the same type of 
device for their asthma controller and reliever therapy.
11
We can speculate why patients prescribed the same device 
type had better outcomes. Specifically, because both ICS drug 
and device were the same in both cohorts, and the SABA for-
mulations in the two devices are the same, it is reasonable to 
conclude that the findings likely relate to the impact of salbuta-
mol inhaler device choice. However, it is the ICS that influences 
asthma control and future risk of asthma exacerbations; SABA 
does not determine asthma control. Therefore, the outcomes in 
this study most likely result from the effect on ICS inhaler tech-
nique of mixing devices, very possibly because the need to use 
different breathing patterns with the two devices adversely im-
pacted ICS inhaler technique.
The strengths of this study include the large patient population 
and the 1-year outcome period, which allowed us to examine 
less frequent outcomes such as hospitalisations and minimised 
the influence of seasonal changes in asthma and allergies. The 
GPRD is an established source for primary care data and draws 
from a geographically and socioeconomically diverse popula-
tion; this improves the generalisability, or applicability, of study 
results to real-world clinical practice. We note that the prescrib-
ing patterns recorded in this study were rational, namely, as the 
ICS dose increased, the percentages of patients meeting the 
study asthma control measure decreased, suggesting that high-
er doses were prescribed for patients with more difficult asthma.
While there were some differences between study cohorts at 
baseline, the two cohorts were comparable in terms of baseline 
asthma control and severe exacerbations. Moreover, the effec-
tiveness analyses adjusted for differences between cohorts de-
termined to be potential confounders. For example, at baseline 
the mixed devices cohort was more likely to use more SABA and 
to have more asthma prescriptions; however, neither of these 
variables had a significant effect on the asthma control outcome 
and thus were omitted from the final model. Instead, for the se-
vere exacerbation outcome, the model was adjusted for base-
line differences in asthma prescriptions.
The composite asthma control endpoint was designed to cap-
ture indicators of asthma control that would be recorded in the 
GPRD, including unscheduled asthma care and hospitalisations, 
oral corticosteroid prescriptions, and antibiotic prescriptions 
for lower respiratory tract infection, as in real-world practice 
asthma exacerbations can be confused for acute respiratory in-
fections.
24,25 There were some significant differences between 
cohorts in the unadjusted results of the disaggregated outcome 
measures, including more patients in the same devices cohort 
who took additional therapy (3.5% vs. 2.5%) and more patients 
in the mixed devices cohort who had a change in inhaler device 
(8.7% in same devices cohort vs. 10.7%) and overall with a 
change in therapy (25.2% same devices vs. 26.6% mixed devices 
cohort); however, these differences were small and unlikely to 
be clinically significant.
Study findings should be interpreted with an understanding 
of potential study limitations, common to observational stud-
ies. These include the potential for unrecognised confounding 
factors, including selection bias. Moreover, while the GPRD is 
recognised to be a high-quality database, there were missing 
data for some patients, including smoking history, that could 
influence outcomes. The smoking status was more likely to be 
recorded for patients with more difficult disease (i.e., those not 
achieving asthma control), a possible explanation for the high 
recorded smoking prevalence (-43%) among the 40% of patients 
with recorded smoking history. While there is no assurance that 
patients actually took the medications as prescribed and dis-
pensed, it is unlikely there would be differences between co-
horts in this parameter that could bias the results. In the UK, 
the pharmacist must dispense as prescribed by the physician, 
and the GPRD prescribing data are considered a reliable proxy 
for dispensed medications.
14,26 Finally, the consistency of the 
outcomes, including the sensitivity analyses, provide support 
for the overall findings.
In conclusion, we found that patients prescribed the same 
BAI device for both controller ICS and reliever salbutamol ther-
apy had better odds of asthma control and lower risk of severe 
exacerbations over 1 year after their first ICS prescription than 
those prescribed a BAI for ICS and a pMDI for salbutamol. These 
findings suggest that, when possible, the same device should 
be prescribed for both ICS and reliever therapy when patients 
are initiating ICS. The devices we studied are relatively similar, 
and it is possible that the adverse effects of mixing other device 
types, such as DPIs and pMDIs, might be greater. Further re-
search is needed to investigate asthma-related outcomes with 
other potential inhaler device combinations and whether con-
sistent device prescribing is optimal also for other inhaler de-
vice types.
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